Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer

Clinical Lung Cancer

Volumn 18, Issue 2, 2017, Pages 234-240.e2

  Okuma, Hitomi Sumiyoshi ^a,b   Horinouchi, Hidehito ^a   Kitahara, Shinsuke ^a   Asao, Tetsuhiko ^a   Sunami, Kuniko ^a   Goto, Yasushi ^a   Kanda, Shintaro ^a   Fujiwara, Yutaka ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Ohe, Yuichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Amrubicin; Salvage chemotherapy; Second line chemotherapy; Small cell lung cancer; Weekly cisplatin plus etoposide plus irinotecan

Indexed keywords

AMRUBICIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; TOPOTECAN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 85006782587     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.09.005     Document Type: Article

References (32)

1. 1 Siegel, R., Ward, E., Brawley, O., Jemal, A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61 (2011), 212–236.
2. 2 Govindan, R., Page, N., Morgensztern, D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006), 4539–4544.
3. 3 Jackman, D.M., Johnson, B.E., Small-cell lung cancer. Lancet 366 (2005), 1385–1396.
4. 4 Witta, S.E., Kelly, K., Chemotherapy for small cell lung cancer. Pass, H.I., Mitchell, J.B., Johnson, D.H., et al. (eds.) Lung Cancer: Principles and Practice, 2005, Lippincott Williams & Wilkins, Philadelphia, PA.
5. 5 Niell, H.B., Herndon, J.E. 2nd, Miller, A.A., et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 (2005), 3752–3759.
6. 6 Evans, W.K., Shepherd, F.A., Feld, R., Osoba, D., Dang, P., Deboer, G., VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3 (1985), 1471–1477.
7. 7 Okamoto, H., Watanabe, K., Nishiwaki, Y., et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 17 (1999), 3540–3545.
8. 8 Noda, K., Nishiwaki, Y., Kawahara, M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002), 85–91.
9. 9 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small-cell lung cancer, version 1.2016. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed: September 15, 2016.
10. 10 Giaccone, G., Donadio, M., Bonardi, G., Testore, F., Calciati, A., Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 6 (1988), 1264–1270.
11. 11 Ardizzoni, A., Hansen, H., Dombernowsky, P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (1997), 2090–2096.
12. 12 Eckardt, J.R., von Pawel, J., Pujol, J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (2007), 2086–2092.
13. 13 von Pawel, J., Gatzemeier, U., Pujol, J.L., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19 (2001), 1743–1749.
14. 14 O'Brien, M.E., Ciuleanu, T.E., Tsekov, H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (2006), 5441–5447.
15. 15 von Pawel, J., Schiller, J.H., Shepherd, F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999), 658–667.
16. 16 von Pawel, J., Jotte, R., Spigel, D.R., et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32 (2014), 4012–4019.
17. 17 Park, S.H., Cho, E.K., Kim, Y., et al. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 62 (2008), 1009–1014.
18. 18 Inoue, A., Sugawara, S., Yamazaki, K., et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26 (2008), 5401–5406.
19. 19 Murakami, H., Yamamoto, N., Shibata, T., et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 84 (2014), 67–72.
20. 20 Ettinger, D.S., Jotte, R., Lorigan, P., et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28 (2010), 2598–2603.
21. 21 Jotte, R., Conkling, P., Reynolds, C., et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 29 (2011), 287–293.
22. 2 in patients with previously treated small-cell lung cancer. Jpn J Clin Oncol 45 (2015), 941–946.
23. 23 Goto, K., Ohe, Y., Shibata, T., et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17 (2016), 1147–1157.
24. 24 Chhatriwala, H., Jafri, N., Salgia, R., A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther 5 (2006), 1600–1607.
25. 25 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
26. 26 Ishizumi, K.O.N., Tanno, N., Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52 (1987), 4477–4485.
27. 27 Morisada, S., Yanagi, Y., Kashiwazaki, Y., Fukui, M., Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 80 (1989), 77–82.
28. 28 Maemondo, M., Inoue, A., Sugawara, S., et al. 1471P: Final result of randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (PTS) with sensitive-relapsed small-cell lung cancer (SCLC): NJLCG0702. Ann Oncol, 25(suppl 4), 2014, iv514.
29. 29 Vasey, P.A., Kaye, S.B., Combined inhibition of topoisomerases I and II–is this a worthwhile/feasible strategy?. Br J Cancer 76 (1997), 1395–1397.
30. 30 Sekine, I., Nishiwaki, Y., Kakinuma, R., et al. Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer 88 (2003), 808–813.
31. 31 Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B., Hansen, H.H., Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J Clin Oncol 13 (1995), 1215–1220.
32. 32 Ettinger, D.S., Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?. J Thorac Oncol 2 (2007), 160–165.